EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects

Sufeng Zhou, Lijun Xie, Chen Zhou, Lu Wang, Juan Chen, Sijia Ding, Bei Zhu, Mei Su, Feng Shao iD

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13598 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Sufeng Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Potassium. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and pharmacodynamics (PDs) of multiple doses of keverprazan. This was a randomized, positive‐/placebo‐controlled, phase Ic trial. Twenty‐six healthy adults were randomized to receive 20 mg/day keverprazan ( n = 8), 40 mg/day keverprazan ( n = 8), placebo ( n = 6), or 20 mg/day vonoprazan ( n = 4) for 7 days. Safety, PK and PD assessments were conducted. In the keverprazan, vonoprazan, and placebo groups, adverse events (AEs) were reported in nine (56.25%), two (50.00%), and three (50.00%) subjects, respectively. AEs were mild except a moderate abdominal pain leading to withdraw. No serious AEs occurred. The plasma concentration‐time profiles of keverprazan showed rapid absorption (median time to maximum plasma concentration of 1.25–3.0 h). The terminal half‐life was 6.23 and 7.01 h for keverprazan 20 and 40 mg groups on day 7. The maximum plasma concentration was 43.1 and 93.2 ng/mL, respectively. There was no apparent accumulation of keverprazan and the major metabolite after 7‐day administration. The intragastric pH greater than 5 holding time ratios (HTRs) over 24 h postdose increased from 79.1%, 84.4%, and 84.5% on day 1 to 99.0%, 97.4%, and 100.0% on day 7 in the vonoprazan 20 mg and keverprazan 20 and 40 mg groups, respectively. The intragastric pH greater than 5 HTR of keverprazan reached a plateau at 20 mg. Keverprazan is well‐tolerable. A steady‐state in exposure was generally reached after 7 days of treatment. A dose of 20 mg/day keverprazan can elicit a significant, stable, and long‐lasting gastric acid inhibition effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PotassiumAdultHumansHealthy VolunteersDose-Response Relationship, DrugDouble-Blind MethodAdministration, OralPyrrolesSulfonamides

Substanzen

Potassium1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamides

Autor:innen und Institutionen

  • Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Jiangsu Carephar Pharmaceutical Co., Ltd., Nanjing, China.
  • Department of Clinical Pharmacology, Pharmacy College, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Feng Shao

Zitieren

APA

Zhou, S., Xie, L., Zhou, C., Wang, L., Chen, J., Ding, S., Zhu, B., Su, M., & Shao, F. (2023). Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.13598

Vancouver

Zhou S, Xie L, Zhou C, Wang L, Chen J, Ding S, et al. Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clinical and Translational Science. 2023. doi:10.1111/cts.13598

BibTeX
@article{Zhou2023,
  author = {Zhou, Sufeng and Xie, Lijun and Zhou, Chen and Wang, Lu and Chen, Juan and Ding, Sijia and Zhu, Bei and Su, Mei and Shao, Feng},
  title = {Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13598}
}
Kostenlos starten →